Form D · Biotechnology
Geneius Biotechnology, Inc.
Natick, MA · CIK 0001636098
Offering snapshot reported Sep 12, 2018 · SEC filing
- Reported sold
- $550K Offering amount: $5M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 23, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 12, 2018 | Initial | $550,000 | No comparison | 7 | SEC filing |
| Jan 6, 2016 | Initial | $2,387,350 | No comparison | 20 | SEC filing |
| Jun 15, 2015 | Initial | $3,062,984 | No comparison | 45 | SEC filing |
| Mar 11, 2015 | Initial | $2,328,667 | No comparison | 34 | SEC filing |
Offering details
- Securities
- Debt, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-321125
Source: Form D, filed Sep 12, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Steven Kloeblen | Director |
| Ryan Lane | Director |
| Alfred E. Slanetz | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
12 Michigan Drive
Natick, MA, 01760
Natick, MA, 01760